

Editorial Board Focus: Dr. Margaret Faul (Amgen, USA)

Background and Purpose. From time to time, SYNFORM portraits Thieme Chemistry Editorial Board or Editorial Advisory Board members who answer several questions regarding their research interests and revealing their impressions and views on the developments in organic chemistry as a general research field. This Editorial Board Focus presents Dr. Margaret Faul (Amgen, USA) who recently joined the Editorial Board of Science of Synthesis as a new member.

Biographical Sketch



Dr. M. Faul

Margaret Faul received her B.Sc. and M.Sc. degrees from University College Dublin (Ireland). She then moved to the USA where she received her Ph.D. degree in Synthetic Organic Chemistry from Harvard University (USA) with Professor David A. Evans. In 1993 Margaret joined the Chemical Process group at Eli Lilly and Company (USA) and in 2003 she moved to Amgen (USA) where she is currently the Executive Director in the Process Development organization. At Amgen, Margaret is responsible for the Commercial Process Development and Process Characterization of all molecules in both the Synthetic and Biologic Amgen Portfolio.

During her 25-year career, Margaret has leveraged her technical experience to support programs across all stages of development from preclinical to commercialization. She has supported the process development and supply of drug substance for clinical trials and commercial products and has significant experience in scale-up and GMP concepts. Margaret has experience working with Commercial Manufacturing Organizations worldwide and an ability to work with partners during licensing activities to ensure seamless integration and development of programs with the partner company. Margaret has a strong knowledge of regulatory and compliance issues as they relate to the development of pharmaceutical products. For her achievements in chemical research management Margaret was recognized as the recipient of the 2018 Earle Barnes recipient for Leadership in Chemical Research Management from the American Chemical Society.

Throughout her industrial career at Amgen, Margaret has invested significant effort in evolving a green chemistry culture focused on implementation of greener and more sustainable chemical processes towards the development of

novel drug substances. These efforts resulted in Amgen being awarded the Presidential Green Chemistry Challenge Award in 2017 in recognition of their work to promote the environmental and economic benefits of novel green chemistry.

Margaret has achieved a strong scientific reputation and has invested significantly in supporting the external scientific efforts. She is a member of the Board of Directors of the International Consortium for Innovation and Quality in the Pharmaceutical Industry and Chair of the Enabling Technologies Consortium. Margaret also has a strong publication record being an author/co-author of more than 150 peer-reviewed publications, presentations and patents. Margaret has served as a symposium organizer and session chair for several major process chemistry events and is has been a member of the Editorial Boards for *Organic Syntheses*, *Journal of Organic Chemistry* and *Organic and Biomolecular Chemistry*.

INTERVIEW

SYNFORM Please could you comment on your new role as a member of the Editorial Board of Science of Synthesis?

Dr. M. Faul I am very excited to join the Editorial Board of Science of Synthesis. This reference work provides valuable information to organic chemists by providing full-text descriptions of organic transformations in the form of critical reviews and, at the same time, experimental procedures. Having recently completed an eight-year term on the Editorial Board of *Organic Syntheses*, I feel this is a good transition for me where I can continue giving back value to the organic synthesis community by providing feedback on the value of the procedures based upon their application in an industrial setting.

SYNFORM *What do you think about the modern role and prospects of synthetic chemistry, in particular its importance in and for the pharmaceutical industry?*

Dr. M. Faul Organic synthesis continues to play a critical role in the pharmaceutical industry and is the basis on which we develop the commercial processes for our new chemical entities (NCEs). Continued learning across industry and academia is key to developing a deep understanding of our chemical processes ensuring that they can be safely applied in a manufacturing setting.

SYNFORM *You are a leading researcher with regard to green chemistry. Could you tell us more about how important you perceive this particular topic to be?*

Dr. M. Faul The pharmaceutical industry is invested in advancing sustainability through the application of green chemistry principles. As demands on our industry for 'right first time' and 'reduced cost and time to market' become ever more critical, my role as a leader in process development is to ensure that we can provide medicines to patients using cost-competitive manufacturing processes that minimize environmental impact.

